The slim-down at Novartis continues, with some eye disease products now reportedly on the chopping block.
Sanofi is set to acquire Provention Bio, picking up the company’s first-in-class treatment to delay stage 3 type 1 diabetes (T1D).
The FDA has granted Orphan Drug status to Ellipses Pharma’s EP0042, an investigational drug for treatment of patients with acute myeloid leukemia.
The FDA has approved Pfizer’s Zavzpret (zavegepant), a nasal spray for acute treatment of adults with migraine, with or without aura.
We use cookies only to remember your preferences and provide better browsing experience. We do not sell user information. Here is our privacy policy.